Evelo Biosciences, Inc. (NASDAQ:EVLO) is set to announce third quarter earning results on Thursday 29th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, EVLO to report 3Q20 loss of $ 0.5 per share.
For the full year, analysts anticipate loss of $ 2.23 per share bottom line.
Stock Performance
Shares of Evelo Biosciences, Inc. traded low $ -0.03 or -0.65 percent on Wednesday, reaching $ 4.56 with volume of 117.50 thousand shares. Evelo Biosciences, Inc. has traded high as $ 4.65 and has cracked $ 4.22 on the downward trend
According to the previous trading day, closing price of $ 4.56, representing a 52.49 % increase from the 52 week low of $ 3.01 and a 43.19 % decrease over the 52 week high of $ 8.08.
The company has a market capital of $ 210.38 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Evelo Biosciences, Inc. will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.evelobio.com
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.
